Acadia Pharmaceuticals Inc. (ACAD)

Last Three Months

21-Jan-24 -- 20-Apr-24

Time Period:

Three Months
|
Year

0 Net Amount

Buy:	0	--
Sell:	0	--

Company Sentiment

Biotechnology

Drugs

Insider Trading Sentiment: Reduce

Insider Trading Sentiment: Reduce

Sentiment Breakdown by Insider

0

(3)

0

(2)

0

(1)

30

0

4

+1

0

+2

0

+3

Two Year Chart

21-Apr-22 -- 20-Apr-24

Price ($)

Two Year Stock Price Chart

Sentiment

Buy & Sell Volume ($)

Two Year Insider Trading Volume Chart

Recent Insider Trades

Last Transaction		Last Three Months
SEC Filing	Transaction	Insider	Sentiment	Company	Holdings Change	Buy Amount	Sell Amount	Buy Price Range	Sell Price Range
09-Apr-24 6:00 PM View:	08-Apr-24 Planned Option Sale ($474.88K)	Davis Stephen CEO Director		Acadia Pharmaceuticals Inc. - ACAD	49% 96.52K to 144.27K	0	0	--	--	Show Txns Hide Txns

09-Apr-24 6:00 PM View:	08-Apr-24 Planned Option Sale ($31.99K)	Kihara James Principal Accounting Officer		Acadia Pharmaceuticals Inc. - ACAD	19% 11.03K to 13.1K	0	0	--	--	Show Txns Hide Txns

09-Apr-24 6:00 PM View:	08-Apr-24 Planned Option Sale ($45.89K)	Teehan Brendan EVP, COO, Head of Commercial		Acadia Pharmaceuticals Inc. - ACAD	25% 30.95K to 38.8K	0	0	--	--	Show Txns Hide Txns

09-Apr-24 6:00 PM View:	08-Apr-24 Planned Option Sale ($48.53K)	Schneyer Mark C. EVP, Chief Financial Officer		Acadia Pharmaceuticals Inc. - ACAD	40% 20.49K to 28.74K	0	0	--	--	Show Txns Hide Txns